Testing a new drug for certain B-cell blood cancers
Part of Blood & lymphatic, Cancer, Heart & circulation, Immune system & allergy clinical trials.
This Phase 1/2 trial studies the safest dose and then effectiveness of BGB-16673 in people with specific B-cell malignancies. It may help by targeting cancer cells in these blood cancers, especially after other treatments like BTK inhibitors.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have one of these diagnoses: marginal zone lymphoma, follicular lymphoma, mantle cell lymphoma, CLL/SLL, Waldenström macroglobulinemia, diffuse large B-cell lymphoma, or Richter transformation to DLBCL
- If you previously took a BTK inhibitor, you had it for at least 8 weeks (unless you had to stop due to side effects)
- If you were treated with a BTK inhibitor before, your cancer must have worsened despite it, or you stopped it because of side effects
- Your cancer must be measurable (scan results) or, for Waldenström macroglobulinemia, you must have a blood IgM level that can be tracked
- Your overall health (ECOG) must be 0 to 2, meaning you can manage daily activities
- For some Phase 2 groups: CLL/SLL needs prior BTK inhibitor plus a prior Bcl-2 inhibitor; mantle cell lymphoma needs a prior BTK inhibitor
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug (BGB-16673) against another drug (pirtobrutinib) for people with CLL or SLL that hasn't responded to or has come back after a prior BTK inhibitor treatment. The goal is to see which drug is more effective and safe.
This trial tests a new investigational drug, BGB-16673, for people with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) who have already tried two types of treatments (BTK and BCL2 inhibitors). The goal is to see if this new drug works better than other available treatments chosen by the doctor.
This early-stage study tests a new medicine (BGB-16673) that targets B-cell cancer cells in people with specific lymphoma or related blood cancers. It aims to see how well the drug can control the cancer and what side effects it causes, especially in Chinese participants.
This study tests new drug combinations for people with B-cell blood cancers (like lymphoma or leukemia) that have come back or stopped responding to treatment. It aims to see if these combos are safe and can help fight the cancer.
This Phase 1 trial studies LP-168 taken by mouth in people whose B-cell cancers have come back or did not respond to treatment. The study aims to find how the drug works, the right dose, and what side effects to expect.
This study tests a new drug called NX-5948 against an existing drug (pirtobrutinib) for patients with chronic lymphocytic leukemia or small lymphocytic lymphoma that has come back or stopped responding to a previous BTK inhibitor treatment. The goal is to see if NX-5948 works better or is safer for this hard-to-treat situation.
Hear when a new Marginal Zone Lymphoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.